Related Experiment Video
Updated: Aug 23, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Cyclooxygenase 2 inhibitors and lung carcinoma]
Jean-Philippe Spano1, Kader Chouahnia, Jean-François Morère
1Hôpital Pitié-Salpêtrière, Département d'oncologie médicale, Bd de l'Hôpital, 75013 Paris. jean-philippe.spano@psl.ap-hop-paris.fr
Abstract:
Cyclooxygenase-2 (Cox2) may play a crucial role in lung carcinogenesis. In fact, overexpression of Cox2 is common in non-small cell lung cancer (NSCLC) and seems to be associated with tumor progression, invasion and metastasis. In experimental animal models Cox2 has been shown to be involved in tumor angiogenesis, suggesting that Cox2 is a potential target for NSCLC therapy. Several in vivo studies have already shown that Cox2 specific inhibitors (celecoxib, rofecoxib) have anti-tumor activity and clinical trials using Cox2 inhibitors are currently ongoing in patients with NSCLC.
Related Concept Videos
Inhibition of Cdk Activity
Chronic Obstructive Pulmonary Disease II: Emphysema
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Positive Regulator Molecules